Patents by Inventor Boris Engels

Boris Engels has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD19 and CD22 chimeric antigen receptors and uses thereof
    Patent number: 11975026
    Abstract: The present disclosure provides compositions and methods for treating diseases associated with expression of CD19 and/or CD22, e.g., by administering a recombinant T cell or natural killer (NK) cell comprising a CD22 CAR and a CD19 CAR as described herein. The disclosure also relates to CAR molecules specific to CD22 and/or CD19, methods of making a cell comprising the same and vectors encoding the same.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: May 7, 2024
    Assignee: Novartis AG
    Inventors: Boris Engels, Carla Patricia Guimaraes
  • Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain
    Patent number: 11872249
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: January 16, 2024
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Barbara Brannetti, Jennifer Brogdon, Boris Engels, Brian Walter Granda, Lu Huang, Ming Lei, Na Li, Jimin Zhang, Carla Patricia Pinto Guimaraes, Saar Gill, Marco Ruella, Regina M. Young
  • METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS
    Publication number: 20230256017
    Abstract: The invention provides methods of making immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods.
    Type: Application
    Filed: February 26, 2021
    Publication date: August 17, 2023
    Inventors: Jennifer BROGDON, Glenn DRANOFF, Michael R. GREENE, Anniesha HACK, Olja KODRASI, Elizabeth Dorothy PRATICO, Andrew PRICE, Andrew Marc STEIN, Amy RAYO, Jennifer YANG, Brian Walter GRANDA, Attilio BONDANZA, Boris ENGELS, Hyungwook LIM, Akash SOHONI, Louise TREANOR, Xu ZHU, Carla GUIMARAES, Shyamali JAYASHANKAR, Sandeep Tharian KOSHY, Regis CEBE, Michael BARDROFF, Sandra MILLER
  • METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS
    Publication number: 20230174933
    Abstract: This disclosure provides methods of making immune effector cells (for example, T cells, NK cells) that comprise (i) a nucleic acid molecule that encodes a controllable chimeric antigen receptor (CCAR) or (ii) a nucleic acid molecule that encodes a CAR and a regulatory molecule, and compositions generated by such methods.
    Type: Application
    Filed: February 26, 2021
    Publication date: June 8, 2023
    Inventors: Jennifer BROGDON, Seth CARBONNEAU, Glenn DRANOFF, Michael R. Greene, Anniesha HACK, Marc Horst Peter HILD, Olja KODRASI, Elizabeth Dorothy PRATICO, Andrew PRICE, Andrew Marc STEIN, Attilio BONDANZA, Boris ENGELS, Carla Patricia Pinto GUIMARAES, Hyungwook LIM, Sujata SHARMA, Akash SOHONI, Louise TREANOR, Xu ZHU
  • Regulatable chimeric antigen receptor
    Patent number: 11578130
    Abstract: Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: February 14, 2023
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Boris Engels, David Jonathan Glass, Brian Granda, John Hastewell, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, William Raj Sellers, Huijuan Song, Brian Edward Vash, Jan Weiler, Qilong Wu, Li Zhou
  • REGULATABLE CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20230026049
    Abstract: Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
    Type: Application
    Filed: April 28, 2022
    Publication date: January 26, 2023
    Inventors: Jennifer Brogdon, Boris Engels, David Jonathan Glass, Brian Granda, John Hastewell, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, William Raj Sellers, Huijuan Song, Brian Edward Vash, Jan Weiler, Qilong Wu, Li Zhou
  • MESOTHELIN CHIMERIC ANTIGEN RECEPTOR (CAR) AND ANTIBODY AGAINST PD-L1 INHIBITOR FOR COMBINED USE IN ANTICANCER THERAPY
    Publication number: 20230000964
    Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.
    Type: Application
    Filed: July 11, 2022
    Publication date: January 5, 2023
    Inventors: Jennifer Brogdon, Hwai Wen Chang, Boris Engels, Gordon James Freeman, Gerhard Johann Frey, Jennifer Marie Mataraza, Reshma Singh, Arlene Helen Sharpe
  • NUCLEIC ACID MOLECULES ENCODING CHIMERIC ANTIGEN RECEPTORS COMPRISING A CD20 BINDING DOMAIN
    Publication number: 20220387486
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
    Type: Application
    Filed: April 30, 2021
    Publication date: December 8, 2022
    Inventors: Barbara Brannetti, Jennifer Brogdon, Boris Engels, Brian Walter Granda, Lu Huang, Ming Lei, Na Li, Jimin Zhang, Carla Patricia Pinto Guimaraes, Saar Gill, Marco Ruella, Regina M. Young
  • METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS
    Publication number: 20220364055
    Abstract: The invention provides methods of making immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods.
    Type: Application
    Filed: August 30, 2019
    Publication date: November 17, 2022
    Inventors: Louise Treanor, Michael R. Greene, Jennifer Brogdon, Boris Engels, Glenn Dranoff, Olja Kodrasi, Hyungwook Lim, Akash Sohoni, Elizabeth Dorothy Pratico, Anniesha Hack, Aida Abujoub, Tony Fleming, Lu Huang, Connie Hong, John Blankenship, Brian Holmberg, Chonghui Zhang, Dexiu Bu, Andrew Price, Xu Zhu, Andrew Stein, Attilio Bondanza
  • Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
    Patent number: 11413340
    Abstract: Provided are compositions for use in methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: August 16, 2022
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania, Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Jennifer Brogdon, Hwai Wen Chang, Boris Engels, Gordon James Freeman, Gerhard Johann Frey, Jennifer Marie Mataraza, Reshma Singh, Arlene Helen Sharpe
  • CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
    Publication number: 20210220404
    Abstract: The invention provides immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions and methods thereof.
    Type: Application
    Filed: November 25, 2020
    Publication date: July 22, 2021
    Inventors: Aida Abujoub, John Blankenship, Attilio Bondanza, Jennifer Brogdon, Dexiu Bu, Serena De Vita, Glenn Dranoff, Boris Engels, Tony Fleming, Brian Walter Granda, Michael R. Greene, Carla Patricia Guimaraes, Anniesha Hack, Brian Holmberg, Connie Hong, Lu Huang, Olja Kodrasi, Joni Waiee Lam, Hyungwook Lim, Elizabeth Dorothy Pratico, Andrew Price, Akash Sohoni, Andrew Marc Stein, Louise Treanor, Chonghui Zhang, Xu Zhu
  • CD19 AND CD22 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
    Publication number: 20210177900
    Abstract: The present disclosure provides compositions and methods for treating diseases associated with expression of CD19 and/or CD22, e.g., by administering a recombinant T cell or natural killer (NK) cell comprising a CD22 CAR and a CD19 CAR as described herein. The disclosure also relates to CAR molecules specific to CD22 and/or CD19, methods of making a cell comprising the same and vectors encoding the same.
    Type: Application
    Filed: November 25, 2020
    Publication date: June 17, 2021
    Inventors: Boris Engels, Carla Patricia Guimaraes
  • Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
    Patent number: 11026976
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: June 8, 2021
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Barbara Brannetti, Jennifer Brogdon, Boris Engels, Brian Walter Granda, Lu Huang, Ming Lei, Na Li, Jimin Zhang, Carla Guimaraes, Saar Gill, Marco Ruella, Regina M. Young
  • REGULATABLE CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20210087279
    Abstract: Provided are compositions and methods relating to regulatable chimeric antigen receptors (RCARs), natural killer cell receptor CARs (NKR-CARs), and regulatable NKR-CARs (RNKR-CARs), where the intracellular signaling or proliferation of the RCAR or RNKR-CAR can be controlled to optimize the use of an RCAR/NKR-CAR- or RNKR-CAR-expressing cell to provide an immune response. Cells can be engineered to express a RNKR-CAR or to express a RCAR and a NKR-CAR (e.g., inhibitory NKR-CAR). For example, a RCAR or RNKR-CAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR or RNKR-CAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
    Type: Application
    Filed: July 28, 2020
    Publication date: March 25, 2021
    Inventors: Boris Engels, Andreas Loew, Michael C. Milone, Li Zhou
  • HUMAN MESOTHELIN CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
    Publication number: 20200407460
    Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor (CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.
    Type: Application
    Filed: January 23, 2020
    Publication date: December 31, 2020
    Inventors: Gregory Beatty, Boris Engels, Neeraja Idamakanti, Carl H. June, Andreas Loew, Huijuan Song, Qilong Wu
  • TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY
    Publication number: 20200377589
    Abstract: The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
    Type: Application
    Filed: January 15, 2020
    Publication date: December 3, 2020
    Inventors: Gregory Beatty, Boris Engels, Neeraja Idamakanti, Carl H. June, Andreas Loew, Michael C. Milone, Huijuan Song, Enxiu Wang, Qilong Wu
  • BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND USES THEREOF
    Publication number: 20200371091
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to a method of administering a BCMA-targeting chimeric antigen receptor (CAR) therapy and an additional therapeutic agent.
    Type: Application
    Filed: November 30, 2018
    Publication date: November 26, 2020
    Inventors: Iulian Pruteanu-Malinici, Keith Mansfield, Boris Engels, Jan J. Melenhorst, Adam David Cohen, Edward A. Stadtmauer, Alfred Garfall, Michael C. Milone, Joseph A. Fraietta
  • Human mesothelin chimeric antigen receptors and uses thereof
    Patent number: 10640569
    Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor(CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: May 5, 2020
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Gregory Beatty, Boris Engels, Neeraja Idamakanti, Carl H. June, Andreas Loew, Huijuan Song, Qilong Wu
  • NUCLEIC ACID MOLECULES ENCODING CHIMERIC ANTIGEN RECEPTORS COMPRISING A CD20 BINDING DOMAIN
    Publication number: 20200113941
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
    Type: Application
    Filed: October 25, 2019
    Publication date: April 16, 2020
    Inventors: Barbara Brannetti, Jennifer Brogdon, Boris Engels, Brian Granda, Lu Huang, Ming Lei, Na Li, Jimin Zhang, Carla Guimaraes
  • Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
    Patent number: RE49847
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
    Type: Grant
    Filed: January 5, 2022
    Date of Patent: February 27, 2024
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Barbara Brannetti, Jennifer Brogdon, Boris Engels, Brian Granda, Lu Huang, Ming Lei, Na Li, Jimin Zhang, Carla Guimaraes, Saar Gill, Marco Ruella, Regina M. Young